keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DAPTA (Adaptavir) is an inhibitor of CCR5, shows potent anti-HIV activities.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 47.00 | |
5 mg | In stock | $ 89.00 | |
10 mg | In stock | $ 155.00 | |
25 mg | In stock | $ 297.00 | |
50 mg | In stock | $ 443.00 | |
100 mg | In stock | $ 639.00 |
Description | DAPTA (Adaptavir) is an inhibitor of CCR5, shows potent anti-HIV activities. |
Targets&IC50 | Gp120CM CM235/sCD4-CCR5:0.32 nM (IC50, in Cf2Th/synR5 cells), Gp120 BaL/sCD4-CCR5:55 pM (IC50, in Cf2Th/synR5 cells) |
In vitro | D-Ala-peptide T-amide (DAPTA), or Peptide T, named for its high threonine content (ASTTTNYT), is a synthetic peptide comprised of eight amino acids (185-192) of the gp120 V2 region and functions as a viral entry inhibitor by targeting selectively CCR5.?The anti-HIV-1 activity of DAPTA was evaluated in M/M infected with R5 HIV-1 strains.?DAPTA at 10(-9) M inhibited HIV-1 replication in M/M by > 90%.?PCR analysis of viral cDNA in M/M showed that DAPTA blocks HIV entry and in this way prevents HIV-1 infection.?Moreover, DAPTA acts as a strong inhibitor and was more active than the non-peptidic CCR5 antagonist TAK-779 in inhibiting apoptosis (mediated by RS HIV-1 strains produced and released by infected M/M) on a neuroblastoma cell line[1] |
Synonyms | DAPTA(TFA), D-Ala-peptide T-amide, Adaptavir |
Molecular Weight | 856.88 |
Formula | C35H56N10O15 |
CAS No. | 106362-34-9 |
keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 10mM
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
DAPTA 106362-34-9 Immunology/Inflammation Microbiology/Virology Proteases/Proteasome HIV Protease CCR HIV DAPTA(TFA) CC chemokine receptor Human immunodeficiency virus D-Ala-peptide T-amide inhibit Adaptavir Inhibitor inhibitor